Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials

Amy C. Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared an article by Eric C. Blackstone, on LinkedIn:

“With the increasing utilization of surrogate endpoints (eg PFS) in cancer clinical trials, the timely collection AND reporting of patient- reported outcomes (PROs) is essential.

This article offers a great overview of the issue.”